New & Noteworthy

September 2023

Alzheimer’s Disease Diagnostics

Beckman Coulter Diagnostics

Beckman Coulter Diagnostics and Fujirebio announce a collaboration to address the clinical need for blood-based Alzheimer’s Disease diagnostics through continued menu expansion on Beckman Coulter’s Access Family of immunoassay analyzers and by leveraging Fujirebio’s assay technology. Initial assay development efforts will focus on the recently introduced DxI 9000 Access immunoassay analyzer and the previously installed base of Access Family immunoassay analyzers. The DxI 9000 Analyzer has shown capability to develop increasingly sensitive and clinically relevant assays, enabling the platform to keep pace with testing requirements as healthcare providers take aim at challenging diseases, such as Alzheimer’s.

  • Beckman Coulter Diagnostics
    For more information, visit
Request More Information

Current Issue